WY-14643 (Pirinixic Acid): Selective PPARα Agonist for Metabolic and Inflammation Research

Executive Summary: WY-14643 (Pirinixic Acid) is a highly selective PPARα agonist (IC₅₀ = 10.11 µM, human PPARα) used to regulate lipid metabolism and inflammation in model systems (APExBIO). Its aliphatic α-substitution enables dual PPARα/γ agonism in the low micromolar range (Bao et al., 2025). WY-14643 downregulates TNF-α-induced VCAM-1 and reduces monocyte adhesion, confirming anti-inflammatory activity. Oral administration in high fat-fed rats (3 mg/kg/day, 2 weeks) improves insulin sensitivity and lowers plasma glucose, triglycerides, and visceral fat. The compound is water-insoluble but soluble in DMSO and ethanol, with storage recommended at -20°C and short-term solution stability.

Biological Rationale

Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors central to lipid metabolism, inflammation, and metabolic disease. PPARα, in particular, modulates fatty acid oxidation and inflammatory responses in liver and vascular tissues (Bao et al., 2025). Dysregulation of PPARα signaling is implicated in metabolic syndrome, atherosclerosis, and certain cancers. Selective agonists like WY-14643 enable dissection of PPARα-driven pathways and therapeutic target validation. Recent multiomics evidence links PPARα activity to tumor microenvironment modulation and TNF-α-mediated inflammation (Bao et al., 2025).

Mechanism of Action of WY-14643 (Pirinixic Acid)

WY-14643 binds PPARα with high selectivity (IC₅₀ = 10.11 µM, human), inducing receptor activation and target gene transcription. This leads to upregulation of genes involved in β-oxidation of fatty acids and downregulation of genes mediating inflammation (e.g., VCAM-1). Aliphatic α-substitution enhances dual agonist activity for PPARα/γ, a feature exploited in balanced metabolic modulation (APExBIO). WY-14643 also influences Kupffer cell-mediated TNFα mRNA elevation and indirectly promotes hepatocyte mitogenesis, showing context-dependent effects on hepatic and vascular inflammation (Bao et al., 2025).

Evidence & Benchmarks

• WY-14643 is a highly selective PPARα agonist with an IC₅₀ of 10.11 µM for human PPARα (APExBIO).
• Aliphatic α-substituted WY-14643 analogs demonstrate dual PPARα/γ agonism in the lower micromolar range (Bao et al., 2025).
• Pretreatment (250 μM, cellular) with WY-14643 significantly down-regulates TNF-α-induced VCAM-1 expression and monocyte adhesion, confirming anti-inflammatory activity (Bao et al., 2025).
• Oral dosing (3 mg/kg/day, 2 weeks) in high fat-fed rats reduces plasma glucose, triglycerides, leptin, and visceral fat, and enhances insulin sensitivity without increasing body weight (APExBIO).
• WY-14643 is insoluble in water but dissolves in DMSO (≥16.2 mg/mL) and ethanol (≥48.8 mg/mL with ultrasonic assistance) (APExBIO).
• In pLELC tumor models, PPAR-α activation by fatty acids modulates the tumor microenvironment via tissue factor (TF) upregulation, a process mechanistically linked to PPARα signaling (Bao et al., 2025).

This article extends the mechanistic and translational focus compared to "WY-14643 (Pirinixic Acid): Advanced Insights into PPARα-D..." by offering denser, benchmarked claims and detailed application limits. For actionable workflows and troubleshooting, see "WY-14643: Selective PPARα Agonist for Metabolic Research", which this article complements with new data on TNF-α-mediated inflammation. For rigorous translational and tumor microenvironment context, "WY-14643 (Pirinixic Acid): Advanced PPARα Modulation for ..." provides additional mechanistic depth.

Applications, Limits & Misconceptions

WY-14643 is validated for:

• Analysis of lipid metabolism and fatty acid oxidation in vitro and in vivo.
• Dissection of insulin sensitivity pathways in metabolic syndrome models.
• Study of anti-inflammatory mechanisms in vascular endothelial cells.
• Investigation of PPARα-driven gene regulation in hepatic and tumor tissues.

Common Pitfalls or Misconceptions

• WY-14643 is not a pan-PPAR agonist; it is selective for PPARα, with dual PPARα/γ activity only in α-substituted analogs under specific conditions.
• The compound does not directly inhibit TNF-α but modulates downstream gene targets (e.g., VCAM-1).
• Insulin sensitivity enhancement is observed in rodent models; human translational efficacy is under investigation.
• WY-14643 is not water-soluble; inappropriate solvent use may confound results.
• It is not intended for diagnostic or clinical use; for research applications only (see APExBIO guidelines).

Workflow Integration & Parameters

• Solubility: Dissolve in DMSO (≥16.2 mg/mL) or ethanol (≥48.8 mg/mL, ultrasonic assistance); avoid aqueous buffers.
• Storage: -20°C; short-term use of solutions recommended.
• Cellular Assays: Typical pretreatment concentrations: 10–250 μM; confirmed anti-inflammatory effects at 250 μM for 24h.
• Animal Studies: 3 mg/kg/day orally for 2 weeks in high-fat diet rodent models; monitor plasma glucose, triglycerides, leptin, and visceral fat.
• Controls: Include vehicle and PPARα-null controls for specificity.

Conclusion & Outlook

WY-14643 (Pirinixic Acid) is a robust tool compound for dissecting PPARα-mediated metabolic and inflammatory pathways. Its well-defined selectivity, dual agonist potential, and reproducible in vitro and in vivo effects underpin its benchmark status in metabolic disorder research. Ongoing studies are clarifying its translational relevance for human disease and its impact on tumor microenvironments. For full specifications and ordering, consult the official APExBIO product page (A4305). Researchers are encouraged to align protocols with validated parameters and to reference detailed mechanistic analyses in the latest peer-reviewed literature (Bao et al., 2025).